ATE131872T1 - LATENCY-ASSOCIATED PEPTIDES AND THEIR USE - Google Patents
LATENCY-ASSOCIATED PEPTIDES AND THEIR USEInfo
- Publication number
- ATE131872T1 ATE131872T1 AT90917236T AT90917236T ATE131872T1 AT E131872 T1 ATE131872 T1 AT E131872T1 AT 90917236 T AT90917236 T AT 90917236T AT 90917236 T AT90917236 T AT 90917236T AT E131872 T1 ATE131872 T1 AT E131872T1
- Authority
- AT
- Austria
- Prior art keywords
- beta
- sequence
- tgf
- mature tgf
- latency
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Abstract
An isolated nucleic acid sequence is provided that comprises a sequence that encodes a latency associated peptide having a molecular weight of about 75,000 when measured by non-reducing SDS-PAGE and capable of antagonizing a biological activity of mature TGF- beta , provided that the sequence does not also encode a mature TGF- beta . The latency associated peptide so produced is useful therapeutically in blocking a deleterious activity of an endogenously released or exogenously administered TGF- beta , alone or in combination with another exogenously administered or endogenously released immune regulator. It is also useful as a cotreatment therapy with mature TGF- beta , which forms a latent associated complex therewith that is activatable at the desired site in vivo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44168089A | 1989-11-22 | 1989-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE131872T1 true ATE131872T1 (en) | 1996-01-15 |
Family
ID=23753857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT90917236T ATE131872T1 (en) | 1989-11-22 | 1990-10-30 | LATENCY-ASSOCIATED PEPTIDES AND THEIR USE |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0502036B1 (en) |
JP (1) | JPH05503003A (en) |
AT (1) | ATE131872T1 (en) |
AU (1) | AU639047B2 (en) |
CA (1) | CA2068204C (en) |
DE (1) | DE69024369T2 (en) |
DK (1) | DK0502036T3 (en) |
ES (1) | ES2083469T3 (en) |
GR (1) | GR3019343T3 (en) |
WO (1) | WO1991008291A2 (en) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05509320A (en) * | 1990-06-25 | 1993-12-22 | オーエスアイ ファーマシューティカルズ,インコーポレイティド | Tissue-induced tumor growth inhibitor, its preparation and method of use |
EP0690873B1 (en) | 1993-03-19 | 2003-06-11 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
US7393682B1 (en) * | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
US7566768B1 (en) | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
US6607884B1 (en) | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
US7332575B2 (en) | 1994-03-18 | 2008-02-19 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species |
US5708142A (en) | 1994-05-27 | 1998-01-13 | Genentech, Inc. | Tumor necrosis factor receptor-associated factors |
EP1382679A3 (en) | 1995-09-08 | 2004-11-10 | Genentech, Inc. | Vascular Endothelial Growth Factor Related Protein (VRP) Antagonists |
US6030945A (en) * | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
US6998116B1 (en) | 1996-01-09 | 2006-02-14 | Genentech, Inc. | Apo-2 ligand |
IL126383A0 (en) | 1996-04-01 | 1999-05-09 | Genentech Inc | Apo-2li and apo-3 apoptosis polypeptides |
US6159462A (en) * | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
US5851984A (en) * | 1996-08-16 | 1998-12-22 | Genentech, Inc. | Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides |
US6462176B1 (en) | 1996-09-23 | 2002-10-08 | Genentech, Inc. | Apo-3 polypeptide |
US6100076A (en) | 1997-01-31 | 2000-08-08 | Genentech, Inc. | O-fucosyltransferase |
AU729158B2 (en) | 1997-01-31 | 2001-01-25 | Genentech Inc. | O-fucosyltransferase |
GB9702943D0 (en) * | 1997-02-13 | 1997-04-02 | Univ Manchester | Wound healing |
US6342369B1 (en) | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
AU2325199A (en) | 1998-01-15 | 1999-08-02 | Genentech Inc. | Apo-2 ligand |
US7141392B2 (en) | 2001-01-09 | 2006-11-28 | Queen Mary And Westfield College | Latent fusion protein |
US6942853B2 (en) | 2001-01-09 | 2005-09-13 | Queen Mary And Westfield College | Latent fusion protein |
KR100844062B1 (en) | 2001-02-21 | 2008-07-07 | 미쓰이 가가쿠 가부시키가이샤 | Catalyst for olefin polymerizaion and method for producing olefin polymers using the catalyst |
KR101008734B1 (en) | 2001-08-29 | 2011-01-14 | 제넨테크, 인크. | Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY |
EP2526960A1 (en) | 2003-03-12 | 2012-11-28 | Genentech, Inc. | Use of BV8 and/or EG-VEGF to promote hematopoiesis |
ES2564187T3 (en) | 2005-04-05 | 2016-03-18 | Yale University | Glutamate modulation agents in the treatment of mental disorders |
JP5602365B2 (en) | 2005-10-25 | 2014-10-08 | ザ・ジョンズ・ホプキンス・ユニバーシティ | Methods and compositions for treating Marfan syndrome and related diseases. |
EP2230252A1 (en) | 2006-03-13 | 2010-09-22 | The Johns Hopkins University | Augmentation of endothelial thromboresistance |
EP2083863B1 (en) | 2006-10-03 | 2015-03-18 | Genzyme Corporation | Antibodies to tgf-beta for use in the treatment of infants at risk of developing bronchopulmonary dysplasia |
US9089564B2 (en) | 2007-03-22 | 2015-07-28 | The Catholic University of Korea Industry-Academic Cooperatior | Use of EC-SOD for treating angiogenesis-mediated eye diseases |
WO2008115039A1 (en) | 2007-03-22 | 2008-09-25 | Industry Academic Cooperation Foundation, The Catholic University Of Korea | Novel use of ec-sod and method for preparing thereof |
JP5628807B2 (en) | 2008-08-18 | 2014-11-19 | ソウル ナショナル ユニバーシティー インダストリー ファウンデーション | Method for regulating cancer metastasis or cancer cell migration by regulating intracellular levels of lysyl tRNA synthetase |
US20110269233A1 (en) | 2008-09-15 | 2011-11-03 | Laetitia Malphettes | Compositions and methods for regulating cell osmolarity |
KR101102485B1 (en) | 2008-10-10 | 2012-01-05 | 서울대학교산학협력단 | Novel use of grs protein or fragment thereof |
ES2584433T3 (en) | 2010-03-12 | 2016-09-27 | Genzyme Corporation | Combination therapy to treat breast cancer |
EP2593126B1 (en) | 2010-07-12 | 2017-09-20 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases |
CA2823154A1 (en) | 2010-12-27 | 2012-07-05 | Lsip, Llc | Ips cells and method for generating same |
EP2737083A1 (en) | 2011-07-27 | 2014-06-04 | INSERM (Institut National de la Santé et de la Recherche Scientifique) | Methods for diagnosing and treating myhre syndrome |
BR112014009789A2 (en) | 2011-10-26 | 2017-04-25 | Seattle Children's Res Inst | cysteamine in the treatment of fibrotic disease |
WO2013077534A1 (en) | 2011-11-23 | 2013-05-30 | Cell Biotech Co., Ltd. | Protein p14 with anti-cancer and anti-allergy activity and pharmaceutical composition comprising the same |
EP3553169B1 (en) | 2011-12-28 | 2021-11-03 | Kyoto Prefectural Public University Corporation | Normalization of culture of corneal endothelial cells |
CN104334196B (en) | 2012-02-16 | 2018-04-10 | Atyr 医药公司 | For treating the Histidyl-tRNA-synthetase of autoimmune disease and inflammatory disease |
US9493744B2 (en) | 2012-06-20 | 2016-11-15 | Genentech, Inc. | Methods for viral inactivation and other adventitious agents |
US20130281355A1 (en) | 2012-04-24 | 2013-10-24 | Genentech, Inc. | Cell culture compositions and methods for polypeptide production |
US9587235B2 (en) | 2013-03-15 | 2017-03-07 | Atyr Pharma, Inc. | Histidyl-tRNA synthetase-Fc conjugates |
JPWO2015064768A1 (en) | 2013-10-31 | 2017-03-09 | 京都府公立大学法人 | Drugs for diseases related to endoplasmic reticulum cell death in corneal endothelium |
WO2015073633A1 (en) | 2013-11-15 | 2015-05-21 | Genentech, Inc. | Methods for viral inactivation using eco-friendly detergents |
KR101619863B1 (en) | 2014-05-23 | 2016-05-24 | 주식회사 제노포커스 | -Novel -glactosidase |
KR101730035B1 (en) | 2015-03-20 | 2017-04-26 | 한국과학기술원 | Variant Microorganism Producing L-Aspartic acid Derivative and Method for Preparing L-Aspartic acid derivatives Using the Same |
KR101839595B1 (en) | 2015-04-13 | 2018-04-26 | 한국과학기술원 | Method for Preparing Various Lactam |
WO2016187312A1 (en) | 2015-05-18 | 2016-11-24 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for treating an alphavirus infection |
KR20160141123A (en) | 2015-05-28 | 2016-12-08 | 주식회사 제노포커스 | Fully active beta-galactosidase mutants and Uses thereof |
KR101702906B1 (en) | 2015-07-15 | 2017-02-22 | 주식회사 제노포커스 | Novel alpha-1,3-glucanse |
KR101756338B1 (en) | 2016-01-15 | 2017-07-10 | 고려대학교 산학협력단 | Variant Microorganism for Producing L-Cystein and Method for Preparing L-Cystein Using thereof |
US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
RU2747557C2 (en) | 2016-08-02 | 2021-05-06 | Вэксинекс, Инк. | Improved methods for obtaining libraries of polynucleotides in smallpox viruses/eukaryotic cells |
CN110536694A (en) | 2017-04-20 | 2019-12-03 | Atyr 医药公司 | For treating pulmonary inflammatory composition and method |
US10920213B2 (en) | 2018-08-02 | 2021-02-16 | Sk Innovation Co., Ltd. | Heat-resistant carbonic anhydrase mutants and composition for capturing carbon dioxide containing the same |
KR102346050B1 (en) | 2019-01-25 | 2022-01-03 | 주식회사 네오믹스 | Novel polypeptides with skin whitening activity and use thereof |
CN116963769A (en) | 2020-09-07 | 2023-10-27 | 吉爱希公司 | Coronavirus-derived receptor binding domain variants with reduced binding affinity for ACE2 and vaccine compositions comprising the same |
KR20220059399A (en) | 2020-11-02 | 2022-05-10 | 한국과학기술원 | Recombinant microorganism with improved production capacity of hydrophobic compounds and membrane engineering method for the production thereof |
KR20220091889A (en) | 2020-12-24 | 2022-07-01 | 한국과학기술원 | Recombinant Microorganism Introduced Glutaric Acid Transporter Gene and Method for Preparing Glutaric Acid Using the Same |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0269408A3 (en) * | 1986-11-26 | 1989-08-30 | Genentech, Inc. | Tgf-beta in the treatment of inflammatory disorders |
AU626524B2 (en) * | 1987-05-29 | 1992-08-06 | Bristol-Myers Squibb Company | Cloning and expression of simian transforming growth factor- beta 1 |
US5221620A (en) * | 1987-10-06 | 1993-06-22 | Oncogen | Cloning and expression of transforming growth factor β2 |
US5236905A (en) * | 1988-08-25 | 1993-08-17 | Oncogen | In vitro method of inhibition of HIV using transforming growth factor-.beta. |
-
1990
- 1990-10-30 WO PCT/US1990/006292 patent/WO1991008291A2/en active IP Right Grant
- 1990-10-30 ES ES90917236T patent/ES2083469T3/en not_active Expired - Lifetime
- 1990-10-30 AT AT90917236T patent/ATE131872T1/en not_active IP Right Cessation
- 1990-10-30 JP JP3500456A patent/JPH05503003A/en active Pending
- 1990-10-30 CA CA002068204A patent/CA2068204C/en not_active Expired - Fee Related
- 1990-10-30 AU AU67440/90A patent/AU639047B2/en not_active Ceased
- 1990-10-30 EP EP90917236A patent/EP0502036B1/en not_active Expired - Lifetime
- 1990-10-30 DE DE69024369T patent/DE69024369T2/en not_active Expired - Fee Related
- 1990-10-30 DK DK90917236.3T patent/DK0502036T3/en active
-
1996
- 1996-03-19 GR GR960400738T patent/GR3019343T3/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU639047B2 (en) | 1993-07-15 |
DK0502036T3 (en) | 1996-05-06 |
AU6744090A (en) | 1991-06-26 |
JPH05503003A (en) | 1993-05-27 |
CA2068204C (en) | 2002-02-12 |
CA2068204A1 (en) | 1991-05-23 |
DE69024369D1 (en) | 1996-02-01 |
WO1991008291A3 (en) | 1991-12-12 |
EP0502036A1 (en) | 1992-09-09 |
DE69024369T2 (en) | 1996-06-13 |
ES2083469T3 (en) | 1996-04-16 |
WO1991008291A2 (en) | 1991-06-13 |
EP0502036B1 (en) | 1995-12-20 |
GR3019343T3 (en) | 1996-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE131872T1 (en) | LATENCY-ASSOCIATED PEPTIDES AND THEIR USE | |
DE69434538D1 (en) | VASCULAR ENDOTHELIAL GROWTH FACTOR 2 | |
DE69428214D1 (en) | TRANSFORMING GROWTH FACTOR ALPHA H1 | |
DE68929551D1 (en) | Human DNase | |
DK1266965T3 (en) | Recombinant antibodies for human therapy | |
EP0158286A3 (en) | A novel human physiologically active polypeptide | |
DK69890D0 (en) | MONOCLONAL ANTIBODIES REACTIVE WITH CACHETIN | |
ATE221125T1 (en) | CLONED GLUTAMINE ACID DECARBOXYLASE | |
ATE321134T1 (en) | HUMAN FC-GAMMA RECEPTOR III | |
PT735818E (en) | INFLAMMATORY PROTEINS OF MACROFAGOS PIM-3 PIM-4 AND PIM-1Y | |
AU4688589A (en) | A method for treatment of endotoxic shock in a mammal | |
ZA922441B (en) | Glial mitogenic factors,their preparation and use | |
DE69024104T2 (en) | Polypeptides and polypeptide analogs with inhibitory activity towards human elastase | |
DE3875108D1 (en) | PHYSIOLOGICALLY ACTIVE POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION. | |
EP0810285A3 (en) | Mutants of human Interleukin-3 | |
ATE131873T1 (en) | CYTOKINE | |
EP0348086A3 (en) | Novel peptides, their use as immuno suppressants and processes for their preparation | |
NO890174L (en) | RECOMBINANT INTERLEUKIN-1ALFA POLYPEPTIDES. | |
AU9743698A (en) | Allelic variant of human stat3 | |
EP0315081A3 (en) | Anti-coagulating protein pp4-x, its preparation and use | |
NO864742D0 (en) | DNA SEQUENCE CODING FOR HUMAN Tissue PLASMINOGEN ACTIVATOR, RECOMBINANT DNA SEQUENCE, TRANSFORMED WITH THESE AND PROCEDURE FOR PREPARING THE PLASMINOGEN ACTIVATOR. | |
Yasuda et al. | Partial purification and characterization of feline gamma-like interferon | |
IT8804860A0 (en) | PROCEDURE FOR THE RECOVERY OF HEAT, WITH POSSIBLE RECOVERY OR USE OF HUMIDITY, SUBMITTED DIRECTLY OR INDIRECTLY FROM THE HUMAN BODY AND DEVICE FOR ITS IMPLEMENTATION. | |
GR3018675T3 (en) | Antibodies to Promoters of colony stimulating factor activity. | |
ITTO930047A0 (en) | SYSTEM FOR ADJUSTING RESISTANCE IN BOTH DIRECTIONS OF MOVEMENT (EXTENSION AND FLEXION), FOR JOINTS OF THE HUMAN BODY (PHYSIOTHERAPY-REHABILITATION-GYMNICAL SECTOR) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
REN | Ceased due to non-payment of the annual fee |